Anti-VEGF use for ROP is expanding beyond bevacizumab and ranibizumab, with aflibercept’s fusion-protein structure conferring systemic exposure characteristics distinct from antibody-based agents.

In this expert perspective from Retina 2026, Michael S. Ip, MD, discusses a study that compared intraocular inflammatory events and side effects in patients treated with aflibercept 2 mg, aflibercept ...

The FDA approved the first interchangeable biosimilars to aflibercept (Eylea) to treat macular degeneration, according to an announcement from the agency. As interchangeable biosimilars, ...

Patients with diabetic macular edema can expect similar BCVA improvements and CST reductions using an aflibercept biosimilar compared with conventional aflibercept. An aflibercept biosimilar is ...

Among 41 patients treated with 8-mg aflibercept, five developed mild sterile intraocular inflammation within 1 to 3 days. All cases resolved with treatment and caused no permanent vision loss. Early ...

Credit: Getty Images. The BLA is supported by data from the pivotal PULSAR and PHOTON trials. The Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application ...

Please provide your email address to receive an email when new articles are posted on . A non-inferiority comparison between aflibercept and bevacizumab as first-line treatment for macular edema ...

P041, an aflibercept biosimilar, showed noninferiority to originator aflibercept (Eylea) in maintaining vision in nAMD patients over 52 weeks. The study involved 168 patients, with 145 completing the ...

Aflibercept is a vascular endothelial growth factor (VEGF) inhibitor first approved for treatment of diabetic macular edema (DME) in July 2014 after several large trials showed it was superior to ...

As we previously reported, on January 11, 2024, Regeneron Pharmaceuticals, Inc. (“Regeneron”) filed a motion seeking to establish a multi-district litigation (“MDL”) encompassing the aflibercept BPCIA ...

On July 1, Samsung Bioepis Co., Ltd. announced that the FDA has approved PYZCHIVA (ustekinumab-ttwe), a biosimilar referencing STELARA (ustekinumab). PYZCHIVA is approved for the treatment of moderate ...

The aim of this study is to evaluate long-term efficacy of intravitreal injections of aflibercept as primary treatment for subfoveal/juxtafoveal myopic choroidal neovascularisation (CNV). Thirty-eight ...